On the public citation graph

Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells

https://doi.org/10.1007/s00262-018-2211-3
0 signed · 71 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/path.4536openalex-snapshot
Efficient molecular subtype classification of high‐grade serous ovarian cancer
inferredcites →https://doi.org/10.1016/j.ygyno.2011.09.039openalex-snapshot
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
inferredcites →https://doi.org/10.1016/s0029-7844(00)00916-9openalex-snapshot
Induction of Ovarian Tumor-Specific CD8+ Cytotoxic T Lymphocytes by Acid-Eluted Peptide-Pulsed Autologous Dendritic Cells
inferredcites →https://doi.org/10.1016/s0140-6736(09)61157-0openalex-snapshot
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
inferredcites →https://doi.org/10.1016/s1470-2045(13)70363-2openalex-snapshot
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
inferredcites →https://doi.org/10.1016/s1470-2045(15)00086-8openalex-snapshot
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30376-xopenalex-snapshot
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
inferredcites →https://doi.org/10.1038/bjc.2015.96openalex-snapshot
Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma
inferredcites →https://doi.org/10.1038/nm1093openalex-snapshot
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
inferredcites →https://doi.org/10.1038/nm863openalex-snapshot
Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity
inferredcites →https://doi.org/10.1038/nrc3322openalex-snapshot
Paths to stemness: building the ultimate antitumour T cell
inferredcites →https://doi.org/10.1056/nejmoa020177openalex-snapshot
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
inferredcites →https://doi.org/10.1056/nejmoa1103799openalex-snapshot
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
inferredcites →https://doi.org/10.1056/nejmoa1504627openalex-snapshot
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1507643openalex-snapshot
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1073/pnas.0503726102openalex-snapshot
Central memory self/tumor-reactive CD8 + T cells confer superior antitumor immunity compared with effector memory T cells
inferredcites →https://doi.org/10.1073/pnas.0611533104openalex-snapshot
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
inferredcites →https://doi.org/10.1097/00002371-199410000-00004openalex-snapshot
Intraperitoneal Adoptive Immunotherapy of Ovarian Carcinoma with Tumor-Infiltrating Lymphocytes and Low-Dose Recombinant Interleukin-2
inferredcites →https://doi.org/10.1097/00002371-200307000-00005openalex-snapshot
Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients
inferredcites →https://doi.org/10.1097/qad.0b013e3282eee548openalex-snapshot
PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status
inferredcites →https://doi.org/10.1111/j.0105-2896.2010.00903.xopenalex-snapshot
TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity
inferredcites →https://doi.org/10.1111/j.1600-065x.2008.00614.xopenalex-snapshot
The impact of T‐cell immunity on ovarian cancer outcomes
inferredcites →https://doi.org/10.1158/1078-0432.ccr-07-4433openalex-snapshot
HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-08-0196openalex-snapshot
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
inferredcites →https://doi.org/10.1158/1078-0432.ccr-10-0041openalex-snapshot
Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients
inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-0116openalex-snapshot
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
inferredcites →https://doi.org/10.1158/1078-0432.ccr-13-0380openalex-snapshot
Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies
inferredcites →https://doi.org/10.1159/000455014openalex-snapshot
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
inferredcites →https://doi.org/10.1172/jci73639openalex-snapshot
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
inferredcites →https://doi.org/10.1182/blood-2008-12-195792openalex-snapshot
Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
inferredcites →https://doi.org/10.1186/s13048-016-0236-9openalex-snapshot
Adoptive immunotherapy against ovarian cancer
inferredcites →https://doi.org/10.1186/s40425-016-0164-7openalex-snapshot
Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
inferredcites →https://doi.org/10.1200/jco.2005.00.240openalex-snapshot
Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma
inferredcites →https://doi.org/10.1200/jco.2005.03.2813openalex-snapshot
Antibody Immunity to the p53 Oncogenic Protein Is a Prognostic Indicator in Ovarian Cancer
inferredcites →https://doi.org/10.1200/jco.2008.16.5449openalex-snapshot
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
inferredcites →https://doi.org/10.1200/jco.2014.58.9093openalex-snapshot
Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells
inferredcites →https://doi.org/10.1200/jco.2014.59.0703openalex-snapshot
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
inferredcites →https://doi.org/10.1200/jco.2015.62.3397openalex-snapshot
Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
inferredcites →https://doi.org/10.1371/journal.pone.0013940openalex-snapshot
Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs)
inferredcites →https://doi.org/10.1371/journal.pone.0030852openalex-snapshot
Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization
inferredcites →https://doi.org/10.1371/journal.pone.0090604openalex-snapshot
The Use of Ovarian Cancer Cells from Patients Undergoing Surgery to Generate Primary Cultures Capable of Undergoing Functional Analysis
inferredcites →https://doi.org/10.4049/jimmunol.0900409openalex-snapshot
Lymphocytes in the Peritoneum Home to the Omentum and Are Activated by Resident Dendritic Cells
inferredcites →https://doi.org/10.4049/jimmunol.1102609openalex-snapshot
Antigen-Independent Induction of Tim-3 Expression on Human T Cells by the Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Is Associated with Proliferation and Is Dependent on the Phosphoinositide 3-Kinase Pathway

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3960138openalex-extracted
inferred← citeshttps://doi.org/10.2139/ssrn.4180533openalex-extracted
inferred← citeshttps://doi.org/10.1007/s00262-024-03710-9openalex-snapshot
Single-Cell Sequencing of Tumour Infiltrating T Cells Efficiently Identifies Tumour-Specific T Cell Receptors Based on the T-Cell Activation Score
inferred← citeshttps://doi.org/10.1007/s11427-025-2958-3openalex-snapshot
Selective expansion of TCF7-expressing tumor-reactive T cell subpopulations during ovarian tumor-infiltrating T cell production ex vivo
inferred← citeshttps://doi.org/10.1016/j.clim.2024.110289openalex-snapshot
Expansion of tumor-infiltrating lymphocytes in non-small cell lung cancer: Clinical potential and efficacy in EGFR mutation subsets
inferred← citeshttps://doi.org/10.1016/j.imlet.2019.12.010openalex-snapshot
Bispecific antibody activated T cells: A newly developed T cells with enhanced proliferation ability and cytotoxicity
inferred← citeshttps://doi.org/10.1016/j.intimp.2022.108522openalex-snapshot
Harnessing self-assembling peptide nanofibers to prime robust tumor-specific CD8 T cell responses in mice
inferred← citeshttps://doi.org/10.1016/j.smim.2019.101306openalex-snapshot
Cellular therapy approaches harnessing the power of the immune system for personalized cancer treatment
inferred← citeshttps://doi.org/10.1038/s41416-019-0384-yopenalex-snapshot
Tumour-reactive T cell subsets in the microenvironment of ovarian cancer
inferred← citeshttps://doi.org/10.1038/s41467-020-14551-2openalex-snapshot
A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity
inferred← citeshttps://doi.org/10.1080/2162402x.2021.2019466openalex-snapshot
Functional and molecular characterization of PD1 + tumor-infiltrating lymphocytes from lung cancer patients
inferred← citeshttps://doi.org/10.1093/jimmun/vkaf259openalex-snapshot
Efficient expansion of tumor-infiltrating lymphocytes from gynecologic cancer
inferred← citeshttps://doi.org/10.1124/jpet.118.254979openalex-snapshot
Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes
inferred← citeshttps://doi.org/10.1136/jitc-2019-000188openalex-snapshot
Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
inferred← citeshttps://doi.org/10.1136/jitc-2022-005755openalex-snapshot
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
inferred← citeshttps://doi.org/10.1136/jitc-2023-008735openalex-snapshot
Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy
inferred← citeshttps://doi.org/10.1186/s12935-019-1043-3openalex-snapshot
S-15 in combination of Akt inhibitor promotes the expansion of CD45RA−CCR7+ tumor infiltrating lymphocytes with high cytotoxic potential and downregulating PD-1+Tim-3+ cells as well as regulatory T cells
inferred← citeshttps://doi.org/10.1186/s40425-018-0422-yopenalex-snapshot
33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
inferred← citeshttps://doi.org/10.1186/s40425-019-0709-7openalex-snapshot
Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma
inferred← citeshttps://doi.org/10.12677/jcpm.2024.32039openalex-snapshot
Research New Progress of Immunotherapy in Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.2147/ott.s221773openalex-snapshot
Application Of Adoptive Immunotherapy In Ovarian Cancer
inferred← citeshttps://doi.org/10.3389/fbioe.2020.01040openalex-snapshot
Bioengineering the Oxygen-Deprived Tumor Microenvironment Within a Three-Dimensional Platform for Studying Tumor-Immune Interactions
inferred← citeshttps://doi.org/10.3389/fimmu.2020.585385openalex-snapshot
Empirical and Rational Design of T Cell Receptor-Based Immunotherapies
inferred← citeshttps://doi.org/10.3390/cancers15020368openalex-snapshot
Patient-Derived In Vitro Models of Ovarian Cancer: Powerful Tools to Explore the Biology of the Disease and Develop Personalized Treatments
inferred← citeshttps://doi.org/10.3390/cancers18183027openalex-snapshot
Standardized Upstream Processing of Ovarian Cancer Surgical Specimens for TIL-Oriented Cellular Workflows
inferred← citeshttps://doi.org/10.3390/cells10030519openalex-snapshot
MiR-200c-3p Contrasts PD-L1 Induction by Combinatorial Therapies and Slows Proliferation of Epithelial Ovarian Cancer through Downregulation of β-Catenin and c-Myc
inferred← citeshttps://doi.org/10.3892/ol.2019.10094openalex-snapshot
Cytokines secreted by human Wharton's jelly stem cells inhibit the proliferation of ovarian cancer (OVCAR3) cells in�vitro
inferred← citeshttps://doi.org/10.48350/165815openalex-snapshot
Functional and molecular characterization of PD1+ tumor-infiltrating lymphocytes from lung cancer patients.
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.